Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, Martin N, Campbell TB, Rytlewski J, Fuller J, Hege K, Munshi NC, Kochenderfer JN. Lin Y, et al. Among authors: rytlewski j. Nat Med. 2023 Sep;29(9):2286-2294. doi: 10.1038/s41591-023-02496-0. Epub 2023 Aug 17. Nat Med. 2023. PMID: 37592106 Free PMC article. Clinical Trial.
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel.
Paiva B, Manrique I, Rytlewski J, Campbell T, Kazanecki CC, Martin N, Anderson LD Jr, Berdeja JG, Lonial S, Raje NS, Lin Y, Moreau P, San-Miguel JF, Munshi NC, Kaiser SM. Paiva B, et al. Among authors: rytlewski j. Blood Cancer Discov. 2023 Sep 1;4(5):365-373. doi: 10.1158/2643-3230.BCD-23-0044. Blood Cancer Discov. 2023. PMID: 37486974 Free PMC article.
Low-Cost, High-Pressure-Synthesized Oxygen-Entrapping Materials to Improve Treatment of Solid Tumors.
Bi J, Witt E, Voltarelli VA, Feig VR, Venkatachalam V, Boyce H, McGovern M, Gutierrez WR, Rytlewski JD, Bowman KR, Rhodes AC, Cook AN, Muller BN, Smith MG, Ramos AR, Panchal H, Dodd RD, Henry MD, Mailloux A, Traverso G, Otterbein LE, Byrne JD. Bi J, et al. Among authors: rytlewski jd. Adv Sci (Weinh). 2023 Apr;10(10):e2205995. doi: 10.1002/advs.202205995. Epub 2023 Feb 2. Adv Sci (Weinh). 2023. PMID: 36727291 Free PMC article.
Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism.
Gutierrez WR, Scherer A, Rytlewski JD, Laverty EA, Sheehan AP, McGivney GR, Brockman QR, Knepper-Adrian V, Roughton GA, Quelle DE, Gordon DJ, Monga V, Dodd RD. Gutierrez WR, et al. Among authors: rytlewski jd. JCI Insight. 2022 Nov 22;7(22):e159419. doi: 10.1172/jci.insight.159419. JCI Insight. 2022. PMID: 36227698 Free PMC article.
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes.
Schroeder BA, LaFranzo NA, LaFleur BJ, Gittelman RM, Vignali M, Zhang S, Flanagan KC, Rytlewski J, Riolobos L, Schulte BC, Kim TS, Chen E, Smythe KS, Wagner MJ, Mantilla JG, Campbell JS, Pierce RH, Jones RL, Cranmer LD, Pollack SM. Schroeder BA, et al. Among authors: rytlewski j. J Immunother Cancer. 2021 Aug;9(8):e002812. doi: 10.1136/jitc-2021-002812. J Immunother Cancer. 2021. PMID: 34465597 Free PMC article.
43 results